Home > Pulmonology > ERS 2022 > Intravenous N-acetylcysteine performs well in hospitalised patients

Intravenous N-acetylcysteine performs well in hospitalised patients

Presented By
Prof. Alberto Papi, University of Ferrara, Italy
ERS 2022
Intravenous N-acetylcysteine demonstrated mucolytic and expectorant efficacy in hospitalised patients with respiratory diseases and abnormal mucus secretion. The agent outperformed placebo in a large, randomised-controlled study. N-acetylcysteine is an established mucolytic and anti-oxidant medicine for acute and chronic respiratory conditions [1]. In severely ill patients, intravenous administration of this agent may be the preferred route. However, no large-scale trials have studied the efficacy of intravenous N-acetylcysteine as a mucolytic and expectorant therapy. To address this gap in the literature, Prof. Alberto Papi (University of Ferrara, Italy) and co-investigators randomised 333 patients with acute respiratory conditions and abnormal mucus secretion 1:1:1 to standard of care plus a 7-day course of intravenous N-acetylcysteine (600mg, twice daily), standard of care plus intravenous ambroxol hydrochloride (30mg, twice daily), or st...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on